Kenvue (KVUE)

• Market cap: $40.5B
• 1 day: -0.42%
• 5 days: 1.30%
• 1 month: -4.26%
• 3 months: -1.63%
• 6 months: 14.43%
• Year to date: -0.85%
• 1 year: 0.57%
• 5 years: -21.56%
• 10 years: -21.56%
• Sector: Materials
• Industry: Perfumes, Cosmetics & Other Toilet Preparations

About: Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Employees: 22,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

24% more capital invested

Capital invested by funds: $35.6B [Q2] → $44.2B (+$8.51B) [Q3]

17% more call options, than puts

Call options by funds: $297M | Put options by funds: $253M

10% more first-time investments, than exits

New positions opened: 121 | Existing positions closed: 110

0% more funds holding

Funds holding: 984 [Q2] → 985 (+1) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 369 | Existing positions reduced: 409

2.51% less ownership

Funds ownership: 102.35% [Q2] → 99.83% (-2.51%) [Q3]

7% less funds holding in top 10

Funds holding in top 10: 15 [Q2] → 14 (-1) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 0% upside
• Avg. target: $24 12% upside
• High target: $27 28% upside

6 analyst ratings

• positive: 2 33%
• neutral: 4 67%
• negative: 0 0%

Barclays Lauren Lieberman 36% 1-year accuracy 32 / 88 met price target	0% downside $21	Equal-Weight Maintained	17 Jan 2025
UBS Peter Grom 41% 1-year accuracy 9 / 22 met price target	9% upside $23	Neutral Maintained	16 Jan 2025
Citigroup Filippo Falorni 41% 1-year accuracy 7 / 17 met price target	0% downside $21	Neutral Maintained	15 Jan 2025
Piper Sandler Korinne Wolfmeyer 36% 1-year accuracy 16 / 45 met price target	23% upside $26	Overweight Upgraded	6 Jan 2025
Deutsche Bank Steve Powers 47% 1-year accuracy 9 / 19 met price target	14% upside $24	Hold Downgraded	12 Dec 2024